Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Breast cancer metastasis significantly impacts patient survival.
• Understanding the molecular mechanisms driving metastasis is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the role of interferon regulatory factor 7 (Irf7) in breast cancer bone metastasis.
• To identify potential therapeutic targets for preventing or treating metastasis.

Main Methods:

• Comparative transcriptome analysis of primary and metastatic breast cancer cells in a mouse model.
• In vivo experiments involving Irf7 restoration, interferon administration, and immune cell deficiency.
• Clinical validation using patient data from over 800 breast cancer cases.

Main Results:

• Irf7 targets a significant number of genes suppressed in bone metastases.
• Restoring Irf7 or administering interferon reduced bone metastasis and prolonged survival in mice.
• Metastasis acceleration in mice lacking interferon receptor or key immune cells highlights the role of host immune signaling.
• High Irf7-regulated gene expression in primary tumors correlates with prolonged bone metastasis-free survival in patients.

Conclusions:

• Irf7 plays a critical role in suppressing breast cancer bone metastasis through interferon signaling to host immune cells.
• An Irf7-driven gene signature in primary tumors can predict bone metastasis-free survival.
• Targeting this innate immune pathway offers a potential therapeutic strategy for breast cancer patients.